JP2021532060A5 - - Google Patents

Info

Publication number
JP2021532060A5
JP2021532060A5 JP2020560463A JP2020560463A JP2021532060A5 JP 2021532060 A5 JP2021532060 A5 JP 2021532060A5 JP 2020560463 A JP2020560463 A JP 2020560463A JP 2020560463 A JP2020560463 A JP 2020560463A JP 2021532060 A5 JP2021532060 A5 JP 2021532060A5
Authority
JP
Japan
Prior art keywords
ligand
inhibitor
nucleic acid
subject
acid base
Prior art date
Application number
JP2020560463A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019212899A5 (https=
JP2021532060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/029402 external-priority patent/WO2019212899A1/en
Publication of JP2021532060A publication Critical patent/JP2021532060A/ja
Publication of JPWO2019212899A5 publication Critical patent/JPWO2019212899A5/ja
Publication of JP2021532060A5 publication Critical patent/JP2021532060A5/ja
Priority to JP2024090213A priority Critical patent/JP7832987B2/ja
Pending legal-status Critical Current

Links

JP2020560463A 2018-04-30 2019-04-26 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム Pending JP2021532060A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090213A JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862664720P 2018-04-30 2018-04-30
US62/664,720 2018-04-30
US201862681557P 2018-06-06 2018-06-06
US62/681,557 2018-06-06
US201862784179P 2018-12-21 2018-12-21
US62/784,179 2018-12-21
PCT/US2019/029402 WO2019212899A1 (en) 2018-04-30 2019-04-26 Methods and systems for selection and treatment of patients with inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090213A Division JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Publications (3)

Publication Number Publication Date
JP2021532060A JP2021532060A (ja) 2021-11-25
JPWO2019212899A5 JPWO2019212899A5 (https=) 2022-05-09
JP2021532060A5 true JP2021532060A5 (https=) 2022-05-09

Family

ID=68386125

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560463A Pending JP2021532060A (ja) 2018-04-30 2019-04-26 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム
JP2024090213A Active JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090213A Active JP7832987B2 (ja) 2018-04-30 2024-06-03 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム

Country Status (21)

Country Link
US (2) US12305236B2 (https=)
EP (2) EP4296285A3 (https=)
JP (2) JP2021532060A (https=)
KR (2) KR20210013062A (https=)
CN (1) CN112368301B (https=)
AU (1) AU2019261933B2 (https=)
CA (1) CA3098720A1 (https=)
DK (1) DK3774897T5 (https=)
ES (1) ES2962715T3 (https=)
FI (1) FI3774897T3 (https=)
HR (1) HRP20231367T1 (https=)
HU (1) HUE063908T2 (https=)
LT (1) LT3774897T (https=)
MA (1) MA52251A (https=)
MD (1) MD3774897T2 (https=)
PL (1) PL3774897T3 (https=)
PT (1) PT3774897T (https=)
RS (1) RS64747B1 (https=)
SI (1) SI3774897T1 (https=)
TW (1) TW202003573A (https=)
WO (1) WO2019212899A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
KR20210130168A (ko) * 2019-02-08 2021-10-29 세다르스-신나이 메디칼 센터 Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
CA3197828A1 (en) * 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4256086A4 (en) * 2020-12-01 2025-01-15 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
EP4562038A1 (en) * 2022-07-27 2025-06-04 Cephalon LLC Anti-tl1a antibody formulations
CA3262839A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
AU2010244640A1 (en) * 2009-03-27 2011-08-11 Merck Serono S.A. Genetic severity markers in Multiple Sclerosis
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011020906A2 (en) * 2009-08-21 2011-02-24 INSERM (Institut National de la Santé et de la Recherche Médicale) sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
JP6124800B2 (ja) 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
CN117264057A (zh) * 2012-04-27 2023-12-22 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
AU2013271336B2 (en) 2012-06-04 2017-11-30 Centre For Digestive Diseases Compositions and methods for treating Crohn's Disease and related conditions and infections
EP3389781B1 (en) 2015-12-15 2021-08-11 University of Miami Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias

Similar Documents

Publication Publication Date Title
JP2021532060A5 (https=)
FI3774897T3 (fi) Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon
Yin et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray
CN107109494B (zh) Il-33介导型疾病的治疗方法和诊断方法
Shin et al. Relation of β2-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure
EP2944961A1 (en) Markers for cancer prognosis and therapy and methods of use
Aloraifi et al. Detection of novel germline mutations for breast cancer in non‐BRCA 1/2 families
Nogueira et al. Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients
JP2019516383A (ja) 悪性疾患を有する患者の予後を推定し、免疫療法に対する応答性を予測する方法
MX2011004763A (es) Polimorfismos geneticos en la degeneracion macular relacionada con la edad.
KR101566064B1 (ko) 연령-관련 황반 변성에서의 유전자 다형성
HK1213295A1 (zh) Vegf多态性和抗血管发生疗法
Hein et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III G epar Q uinto study
JPWO2019212899A5 (https=)
Onrat et al. Prevalence of myocardial infarction polymorphisms in Afyonkarahisar, Western Turkey
WO2016059239A1 (en) Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
Tavakol et al. Interleukin-6 and tumor necrosis factor-alpha gene polymorphisms in chronic idiopathic urticaria
Urabe et al. Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long‐Term Effect of Infliximab against Crohn’s Disease
CA2724348A1 (en) Genotype and expression analysis for use in predicting outcome and therapy selection
Živković et al. Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis
EP2064347A2 (en) Methods for the identification, evaluation and treatment of patients having cc-chemokine receptor 2(ccr-2) mediated disorders
EP2895624B1 (en) Methods of predicting the development of amd based on chromosome 1 and chromosome 10
Han et al. CCR5 gene polymorphism is a genetic risk factor for radiographic severity of rheumatoid arthritis
Kashiwabara et al. Gene polymorphism and frequencies of the NPC 1L1 Gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia
Frenzel et al. Sustained NF‐kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus